Erythema multiforme - Eritèm Multiforme
☆ AI Dermatology — Free Service
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Erythema multiforme minor ― Remake: byen ke sant blesi yo ka blanchi.
Urtikarya ka konsidere tou kòm yon dyagnostik diferansyèl.
relevance score : -100.0%
ReferencesErythema multiforme (EM) se yon kondisyon kote tach diferan ki sanble ak sib parèt sou po a ak sou manbràn mukozal yo, akòz reyaksyon iminitè. Malgre ke souvan deklanche pa enfeksyon viral, espesyalman viris èpès senp (HSV), oswa pa sèten medikaman, kòz la rete enkoni nan anpil ka. Trete EM konsantre sou soulaje sentòm yo lè l sèvi avèk krèm ki gen estewoyid oswa antihistamin. Jere EM pi efikas lè li adapte pou chak pasyan. Apwòch inisyal enplike tou de tretman oral ak topikal. Men sa yo enkli kortikoterapi ak medikaman antiviral. Tretman topikal konpoze de krèm estewoyid fò ak solisyon pou manbràn mukozal ki afekte yo. Pou pasyan ki pa reponn a antiviral, opsyon dezyèm liy yo enkli dwòg iminitè, antibyotik, anthelmintics, ak antimalarial.
Erythema multiforme (EM) is an immune-mediated condition that classically presents with discrete targetoid lesions and can involve both mucosal and cutaneous sites. While EM is typically preceded by viral infections, most notably herpes simplex virus (HSV), and certain medications, a large portion of cases are due to an unidentifiable cause. Treatment for acute EM is focused on relieving symptoms with topical steroids or antihistamines. Treatment for recurrent EM is most successful when tailored to individual patients. First line treatment for recurrent EM includes both systemic and topical therapies. Systemic therapies include corticosteroid therapy and antiviral prophylaxis. Topical therapies include high-potency corticosteroids, and antiseptic or anesthetic solutions for mucosal involvement. Second-line therapies for patients who do not respond to antiviral medications include immunosuppressive agents, antibiotics, anthelmintics, and antimalarials
Erythema multiforme (EM) is an immune-mediated condition that classically presents with discrete targetoid lesions and can involve both mucosal and cutaneous sites. While EM is typically preceded by viral infections, most notably herpes simplex virus (HSV), and certain medications, a large portion of cases are due to an unidentifiable cause. Treatment for acute EM is focused on relieving symptoms with topical steroids or antihistamines. Treatment for recurrent EM is most successful when tailored to individual patients. First line treatment for recurrent EM includes both systemic and topical therapies. Systemic therapies include corticosteroid therapy and antiviral prophylaxis. Topical therapies include high-potency corticosteroids, and antiseptic or anesthetic solutions for mucosal involvement. Second-line therapies for patients who do not respond to antiviral medications include immunosuppressive agents, antibiotics, anthelmintics, and antimalarials
Nan anpil ka, erythema multiforme modere disparèt poukont li an 2 a 4 semèn. Sendwòm Stevens-Johnson, yon kondisyon grav ki afekte manbràn mikoz yo, ka dire jiska 6 semèn. Estewoyid pa tipikman rekòmande pou ka grav. Si wi oswa non estewoyid yo ta dwe itilize pou erythema multiforme grav, se ensèten paske pa gen okenn rezilta klè nan etid owaza ki montre ki timoun ki ta benefisye de tretman sa a.
In most cases, mild erythema multiforme is self-limited and resolves in 2 to 4 weeks. Stevens-Johnson syndrome is a serious disease that involves the mucous membranes and lasts up to 6 weeks. There is no indication for using steroids for the mild form. Use of steroids for erythema multiforme major is debatable because no randomized studies clearly indicate which children will benefit from this treatment.
In most cases, mild erythema multiforme is self-limited and resolves in 2 to 4 weeks. Stevens-Johnson syndrome is a serious disease that involves the mucous membranes and lasts up to 6 weeks. There is no indication for using steroids for the mild form. Use of steroids for erythema multiforme major is debatable because no randomized studies clearly indicate which children will benefit from this treatment.
Nou prezante yon ka erythema multiforme (EM) oral ki te koze pa TMP/SMX, ki montre tipik maladi ilsè oral ak lèv san blesi po. Sa a souliye bezwen pou diferansye li de lòt maladi ilsè oral. Pasyan an te resevwa tretman pou sentòm ak tablèt prednisolone, ki mennen nan amelyorasyon apre yo fin sispann terapi TMP/SMX.
We report a case of oral erythema multiforme (EM) secondary to TMP/SMX that presented with oral and lip ulcerations typical of EM without any skin lesions and highlights the importance of distinguishing them from other ulcerative disorders involving oral cavity. The patient was treated symptomatically and given tablet prednisolone. The condition improved with stoppage of TMP/SMX therapy.
We report a case of oral erythema multiforme (EM) secondary to TMP/SMX that presented with oral and lip ulcerations typical of EM without any skin lesions and highlights the importance of distinguishing them from other ulcerative disorders involving oral cavity. The patient was treated symptomatically and given tablet prednisolone. The condition improved with stoppage of TMP/SMX therapy.
Erythema multiforme se yon reyaksyon ki afekte po a, epi pafwa mukoza a, ki deklanche pa sistèm iminitè a. Tipikman, li manifeste kòm blesi ki sanble ak sib, ki ka parèt izole, repete, oswa pèsiste. Blesi sa yo anjeneral simetrik, epi yo afekte ekstremite yo, patikilyèman sifas ekstèn yo. Kòz prensipal yo enkli enfeksyon tankou viris èpès senp ak Mycoplasma pneumoniae, osi byen ke sèten medikaman, vaksinasyon, ak maladi otoiminitè. Distinction ant erythema multiforme ak urtikè depann sou dire blesi yo; blesi erythema multiforme rete fiks pou omwen sèt jou, pandan ke blesi urtikè souvan disparèt an 24 èdtan. Malgre kèk similitud, li enpòtan anpil pou diferansye erythema multiforme ak sendwòm Stevens‑Johnson ki pi grav, ki tipikman prezante makil eritematoz oswa purpurik toupatou ak ti anpoul. Jere erythema multiforme mande soulajman sentòm ak itilizasyon estewoyid oswa antihistamin, ansanm ak adrese kòz ki kache a. Pou ka ki asosye ak viris èpès senp, yo rekòmande terapi antiviral pwòfylaktik. Ka ki grav ka bezwen entène lopital pou administrasyon likid intravenèl ak ranplasman elektwolit.
Erythema multiforme is a reaction involving the skin and sometimes the mucosa, triggered by the immune system. Typically, it manifests as target-like lesions, which may appear isolated, recur, or persist. These lesions usually symmetrically affect the extremities, particularly their outer surfaces. The main causes include infections like herpes simplex virus and Mycoplasma pneumoniae, as well as certain medications, immunizations, and autoimmune diseases. Distinguishing erythema multiforme from urticaria relies on the duration of lesions; erythema multiforme lesions remain fixed for at least seven days, while urticarial lesions often vanish within a day. Although similar, it's crucial to differentiate erythema multiforme from the more severe Stevens-Johnson syndrome, which typically presents widespread erythematous or purpuric macules with blisters. Managing erythema multiforme involves symptomatic relief with topical steroids or antihistamines and addressing the underlying cause. For recurrent cases associated with herpes simplex virus, prophylactic antiviral therapy is recommended. Severe mucosal involvement may necessitate hospitalization for intravenous fluids and electrolyte replacement.
Erythema multiforme is a reaction involving the skin and sometimes the mucosa, triggered by the immune system. Typically, it manifests as target-like lesions, which may appear isolated, recur, or persist. These lesions usually symmetrically affect the extremities, particularly their outer surfaces. The main causes include infections like herpes simplex virus and Mycoplasma pneumoniae, as well as certain medications, immunizations, and autoimmune diseases. Distinguishing erythema multiforme from urticaria relies on the duration of lesions; erythema multiforme lesions remain fixed for at least seven days, while urticarial lesions often vanish within a day. Although similar, it's crucial to differentiate erythema multiforme from the more severe Stevens-Johnson syndrome, which typically presents widespread erythematous or purpuric macules with blisters. Managing erythema multiforme involves symptomatic relief with topical steroids or antihistamines and addressing the underlying cause. For recurrent cases associated with herpes simplex virus, prophylactic antiviral therapy is recommended. Severe mucosal involvement may necessitate hospitalization for intravenous fluids and electrolyte replacement.
Kondisyon an varye soti nan yon gratèl ki pa grav, ki limite a po a, rive nan yon fòm grav ki menase lavi, ki rele eritem multiforme majè e ki enplike tou manbràn mikez. Envazyon manbràn mikez la oswa prezans bullaes se siy enpòtan de severite.
- Erythema multiforme minor : blesi tipik ki leve sou po a, papil ak edèm ki distribiye simetrikman.
Fòm sa a anjeneral prezante ak ti gratèl (men demanjezon ka grav), tach woz‑wouj, aranjman simetrik epi kòmanse sou ekstremite yo. Rezolisyon gratèl la an 7‑10 jou se nòmal pou fòm sa a.
- Erythema multiforme major : blesi tipik ki leve, papil ak edèm ki distribiye simetrikman, ak patisipasyon youn oswa plis manbràn mikez. Detachman epidèm enplike mwens pase 10 % nan sifas kò total.
○ Tretman – Medikaman OTC
Si li akonpaye pa lafyèv (k ap ogmante tanperati kò a), li rekòmande pou ale lopital pi vit posib.
Dwòg ki sispèk pou koze kondisyon an dwe sispann (egzanp antibyotik, dwòg anti‑enflamatwa ki pa esteroyid).
Antihistamin oral tankou cetirizine ak loratadine pou soulaje demanjezon.
#Cetirizine [Zytec]
#LevoCetirizine [Xyzal]
#Loratadine [Claritin]